NCT02252107View on ClinicalTrials.gov

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

decitabine

Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.

Trial Locations (3)

Unknown

University of Liège, Liège

University Medical Center Groningen (UMCG), Groningen

6500 HB

Radboud university medical center, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT02252107 - 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 | Biotech Hunter | Biotech Hunter